ANI PHARMACEUTICALS Business Summary

ANI Pharmaceuticals Inc. (ANIP) is a diversified biopharmaceutical company that generates revenue through the development, manufacturing, and commercialization of high-value prescription therapeutics across three primary segments: Rare Disease, Generics, and Established Brands. As of February 2026, the company has successfully pivoted its business model to prioritize its Rare Disease portfolio, which is projected to account for approximately 60% of its $1.1 billion annual revenue guidance. This growth is anchored by its lead asset, Purified Cortrophin Gel, alongside the ophthalmology products ILUVIEN and YUTIQ acquired via the 2024 Alimera Sciences transaction. ANIP competes directly with specialty and generic giants such as Amneal Pharmaceuticals, Teva, and Keenova Therapeutics (formerly Mallinckrodt), whose Acthar Gel is the primary rival to Cortrophin. The company distinguishes itself by leveraging a robust U.S.-based manufacturing footprint and high-barrier-to-entry generic R&D to fund its expansion into the high-margin orphan drug market. The leadership team is spearheaded by President and CEO Nikhil Lalwani, who joined in 2020 following a successful tenure as CEO of Cipla USA and InvaGen, bringing deep expertise in global respiratory and specialty pharmaceutical integration. He is supported by CFO Stephen P. Carey, a 30-year finance veteran formerly of Par Pharmaceutical and Schering-Plough, and Muthusamy Shanmugam, the Head of R&D and COO of NJ Operations, who joined the firm through the strategic acquisition of Novitium Pharma. In late 2025, the company transitioned its board leadership, electing Thomas J. Haughey—formerly General Counsel at Par Pharmaceutical—as Chairman of the Board to succeed the retiring Patrick D. Walsh. Other notable board members include Jeanne Thoma, former CEO of SPI Pharma, and Dr. Renee Tannenbaum, highlighting a pedigree of deep operational and clinical experience in the life sciences sector.